Phreesia, Inc. (NYSE:PHR) CFO Sells $159,135.37 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 5,827 shares of Phreesia stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total value of $159,135.37. Following the completion of the sale, the chief financial officer now directly owns 141,846 shares in the company, valued at $3,873,814.26. This represents a 3.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The stock was sold at an average price of $26.98, for a total value of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Stock Performance

PHR stock opened at $27.29 on Thursday. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $29.16. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average price is $23.77 and its 200 day moving average price is $22.94.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.58) earnings per share. As a group, research analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versor Investments LP purchased a new stake in shares of Phreesia during the third quarter worth about $694,000. Zacks Investment Management acquired a new stake in Phreesia during the third quarter worth approximately $631,000. Sei Investments Co. raised its holdings in Phreesia by 135.3% in the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after acquiring an additional 95,058 shares during the last quarter. State Street Corp lifted its stake in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after purchasing an additional 88,517 shares during the period. Finally, Barclays PLC lifted its stake in shares of Phreesia by 83.6% during the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after purchasing an additional 43,225 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on PHR shares. Truist Financial increased their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a report on Friday, January 10th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. KeyCorp increased their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Finally, Robert W. Baird reduced their price target on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.